Antibody drug conjugate (ADC) therapies are an emerging treatment for hematologic and solid organ malignant tumors. These ADCs are targeted monoclonal antibodies conjugated to a cytotoxic payload, designed to maximize antitumor effect while minimizing toxic effects to normal host tissue.1 We describe a case series of 6 patients who presented with a similar telangiectatic rash after treatment with ADCs containing the cytotoxic payload tesirine.
Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA. Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies. JAMA Dermatol. 2020;156(5):601–603. doi:10.1001/jamadermatol.2020.0208
Dermatology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.